STERIS (STE) Stock Forecast, Price Target & Predictions
STE Stock Forecast
STERIS stock forecast is as follows: an average price target of $262.50 (represents a 19.17% upside from STE’s last price of $220.28) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
STE Price Target
The average price target for STERIS (STE) is $262.50 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $265.00 to $260.00. This represents a potential 19.17% upside from STE's last price of $220.28.
STE Analyst Ratings
According to 4 Wall Street analysts, STERIS's rating consensus is 'Buy'. The analyst rating breakdown for STE stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
STERIS Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 24, 2024 | Jason Bednar | Piper Sandler | $260.00 | $221.15 | 17.57% | 18.03% |
| Sep 03, 2024 | Brett Fishbin | KeyBanc | $265.00 | $241.10 | 9.91% | 20.30% |
| May 10, 2024 | Jason Bednar | Piper Sandler | $225.00 | $225.94 | -0.42% | 2.14% |
| Apr 04, 2024 | Mike Polark | Wolfe Research | $245.00 | $216.65 | 13.09% | 11.22% |
The latest STERIS stock forecast, released on Oct 24, 2024 by Jason Bednar from Piper Sandler, set a price target of $260.00, which represents a 17.57% increase from the stock price at the time of the forecast ($221.15), and a 18.03% increase from STE last price ($220.28).
STERIS Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 4 |
| Avg Price Target | - | - | $248.75 |
| Last Closing Price | $220.28 | $220.28 | $220.28 |
| Upside/Downside | -100.00% | -100.00% | 12.92% |
In the current month, the average price target of STERIS stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to STERIS's last price of $220.28. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 24, 2024 | Stephens | Market Outperform | Market Outperform | Hold |
| Oct 24, 2024 | Piper Sandler | Underperform | Underperform | Hold |
| Oct 24, 2024 | Piper Sandler | Neutral | Overweight | Upgrade |
| Sep 03, 2024 | Stephens | Market Outperform | Market Outperform | Hold |
| Sep 03, 2024 | JMP Securities | Underperform | Underperform | Hold |
| Sep 03, 2024 | KeyBanc | Overweight | Overweight | Hold |
| Aug 07, 2024 | Stephens | Market Outperform | Market Outperform | Hold |
| Jun 10, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| May 10, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Apr 04, 2024 | Wolfe Research | Outperform | Outperform | Hold |
| Feb 09, 2024 | Stephens | Market Outperform | Market Outperform | Hold |
| Aug 03, 2023 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
STERIS's last stock rating was published by Stephens on Oct 24, 2024. The company gave STE a "Market Outperform" rating, the same as its previous rate.
STERIS Financial Forecast
STERIS Revenue Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.40B | $1.34B | $1.28B | $1.38B | $1.22B | $1.20B | $1.16B | $1.21B | $968.42M | $1.20B | $1.21B | $873.53M | $668.93M | $756.13M | $808.92M | $822.99M | $696.80M |
| Avg Forecast | $1.69B | $1.55B | $1.49B | $1.44B | $1.58B | $1.47B | $1.41B | $1.36B | $1.49B | $1.38B | $1.33B | $1.27B | $1.41B | $1.35B | $1.30B | $1.21B | $1.27B | $1.27B | $1.22B | $1.22B | $1.17B | $1.19B | $1.15B | $904.86M | $876.22M | $793.03M | $719.54M | $643.38M | $799.57M | $748.45M |
| High Forecast | $1.71B | $1.56B | $1.51B | $1.46B | $1.59B | $1.48B | $1.42B | $1.37B | $1.50B | $1.39B | $1.33B | $1.27B | $1.41B | $1.36B | $1.31B | $1.22B | $1.29B | $1.28B | $1.22B | $1.22B | $1.17B | $1.19B | $1.15B | $904.86M | $876.22M | $793.03M | $719.54M | $643.38M | $799.57M | $748.45M |
| Low Forecast | $1.66B | $1.53B | $1.48B | $1.42B | $1.56B | $1.45B | $1.39B | $1.34B | $1.48B | $1.37B | $1.33B | $1.27B | $1.41B | $1.34B | $1.28B | $1.19B | $1.26B | $1.26B | $1.22B | $1.22B | $1.17B | $1.19B | $1.15B | $904.86M | $876.22M | $793.03M | $719.54M | $643.38M | $799.57M | $748.45M |
| # Analysts | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 5 | 4 | 1 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 15 | 9 | 9 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 1.03% | 1.06% | 1.09% | 0.96% | 0.98% | 0.95% | 1.03% | 0.81% | 1.04% | 1.34% | 1.00% | 0.84% | 1.05% | 1.26% | 1.03% | 0.93% |
STERIS's average Quarter revenue forecast for Mar 24 based on 1 analysts is $1.41B, with a low forecast of $1.41B, and a high forecast of $1.41B. STE's average Quarter revenue forecast represents a 1.13% increase compared to the company's last Quarter revenue of $1.40B (Dec 23).
STERIS EBITDA Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 5 | 4 | 1 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 15 | 9 | 9 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $216.16M | $185.86M | $188.92M | $226.12M | $190.88M | $318.09M | $158.45M | $91.92M | $76.47M | $230.90M | $322.78M | $203.66M | $165.41M | $196.79M | $205.17M | $208.54M | $158.58M |
| Avg Forecast | $423.98M | $388.76M | $375.91M | $362.47M | $396.45M | $368.69M | $354.03M | $341.79M | $375.97M | $347.58M | $334.60M | $320.02M | $344.19M | $339.16M | $326.75M | $303.66M | $312.90M | $527.34M | $240.36M | $240.60M | $284.45M | $234.89M | $226.54M | $177.97M | $224.86M | $155.98M | $141.52M | $126.54M | $200.70M | $147.21M |
| High Forecast | $428.84M | $393.21M | $380.21M | $366.62M | $401.00M | $372.91M | $358.09M | $345.71M | $378.48M | $350.10M | $334.62M | $320.02M | $413.03M | $341.69M | $330.36M | $307.14M | $375.48M | $632.80M | $240.36M | $240.60M | $341.34M | $234.89M | $226.54M | $177.97M | $269.84M | $155.98M | $141.52M | $126.54M | $240.85M | $147.21M |
| Low Forecast | $418.65M | $383.86M | $371.18M | $357.91M | $391.47M | $364.05M | $349.58M | $337.49M | $370.96M | $345.06M | $334.57M | $320.02M | $275.35M | $336.63M | $322.57M | $299.84M | $250.32M | $421.87M | $240.36M | $240.60M | $227.56M | $234.89M | $226.54M | $177.97M | $179.89M | $155.98M | $141.52M | $126.54M | $160.56M | $147.21M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.64% | 0.57% | 0.62% | 0.72% | 0.36% | 1.32% | 0.66% | 0.32% | 0.33% | 1.02% | 1.81% | 0.91% | 1.06% | 1.39% | 1.62% | 1.04% | 1.08% |
1 analysts predict STE's average Quarter EBITDA for Mar 24 to be $344.19M, with a high of $413.03M and a low of $275.35M. This is 59.23% upper than STERIS's previous annual EBITDA (Dec 23) of $216.16M.
STERIS Net Income Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 5 | 4 | 1 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 15 | 9 | 9 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $140.74M | $115.32M | $123.55M | $187.22M | $123.83M | $-315.23M | $111.26M | $52.26M | $-21.90M | $69.81M | $-21.81M | $88.85M | $88.12M | $105.86M | $88.19M | $123.32M | $104.93M |
| Avg Forecast | $317.04M | $280.14M | $262.56M | $244.96M | $283.23M | $252.31M | $235.11M | $226.02M | $260.06M | $230.44M | $210.60M | $196.14M | $147.46M | $215.13M | $198.74M | $184.52M | $134.05M | $144.21M | $197.10M | $190.31M | $121.87M | $194.98M | $180.86M | $148.27M | $96.34M | $150.89M | $125.88M | $97.19M | $118.63M | $141.11M |
| High Forecast | $321.76M | $284.32M | $266.47M | $248.61M | $287.45M | $256.07M | $238.62M | $229.39M | $261.06M | $234.41M | $211.15M | $196.15M | $176.95M | $217.12M | $204.67M | $187.27M | $160.87M | $173.05M | $197.10M | $190.31M | $146.24M | $198.48M | $180.86M | $148.27M | $115.61M | $150.89M | $125.88M | $97.19M | $142.36M | $141.11M |
| Low Forecast | $311.85M | $275.56M | $258.27M | $240.96M | $278.59M | $248.18M | $231.27M | $222.32M | $255.80M | $227.46M | $210.04M | $196.13M | $117.97M | $214.13M | $187.86M | $181.50M | $107.24M | $115.37M | $197.10M | $190.31M | $97.49M | $191.47M | $180.86M | $148.27M | $77.07M | $150.89M | $125.88M | $97.19M | $94.91M | $141.11M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.65% | 0.58% | 0.67% | 1.40% | 0.86% | -1.60% | 0.58% | 0.43% | -0.11% | 0.39% | -0.15% | 0.92% | 0.58% | 0.84% | 0.91% | 1.04% | 0.74% |
STERIS's average Quarter net income forecast for Mar 24 is $147.46M, with a range of $117.97M to $176.95M. STE's average Quarter net income forecast represents a 4.77% increase compared to the company's last Quarter net income of $140.74M (Dec 23).
STERIS SG&A Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 5 | 4 | 1 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 15 | 9 | 9 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $360.52M | $380.65M | $359.06M | $335.91M | $305.14M | $323.19M | $334.63M | $453.64M | $393.75M | $344.80M | $310.56M | $221.07M | $155.17M | $172.71M | $182.37M | $189.06M | $178.78M |
| Avg Forecast | $440.10M | $403.53M | $390.20M | $376.24M | $411.52M | $382.70M | $367.49M | $354.78M | $390.26M | $360.79M | $347.31M | $332.18M | $366.90M | $352.05M | $339.17M | $315.21M | $333.54M | $311.84M | $317.71M | $318.04M | $303.22M | $310.48M | $299.44M | $235.25M | $239.70M | $206.18M | $187.07M | $167.27M | $181.88M | $194.58M |
| High Forecast | $445.14M | $408.16M | $394.67M | $380.56M | $416.24M | $387.08M | $371.70M | $358.85M | $392.86M | $363.40M | $347.34M | $332.18M | $440.28M | $354.68M | $342.92M | $318.82M | $400.25M | $374.21M | $317.71M | $318.04M | $363.86M | $310.48M | $299.44M | $235.25M | $287.64M | $206.18M | $187.07M | $167.27M | $218.26M | $194.58M |
| Low Forecast | $434.56M | $398.45M | $385.29M | $371.51M | $406.35M | $377.88M | $362.87M | $350.32M | $385.06M | $358.17M | $347.29M | $332.18M | $293.52M | $349.42M | $334.83M | $311.24M | $266.83M | $249.47M | $317.71M | $318.04M | $242.58M | $310.48M | $299.44M | $235.25M | $191.76M | $206.18M | $187.07M | $167.27M | $145.51M | $194.58M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | 1.12% | 1.14% | 1.01% | 0.98% | 1.02% | 1.05% | 1.50% | 1.27% | 1.15% | 1.32% | 0.92% | 0.75% | 0.92% | 1.09% | 1.04% | 0.92% |
STERIS's average Quarter SG&A projection for Mar 24 is $366.90M, based on 1 Wall Street analysts, with a range of $293.52M to $440.28M. The forecast indicates a 1.77% rise compared to STE last annual SG&A of $360.52M (Dec 23).
STERIS EPS Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 5 | 4 | 1 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 15 | 9 | 9 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.42 | $1.17 | $1.25 | $1.89 | $1.24 | $-3.15 | $1.11 | $0.52 | $-0.24 | $0.70 | $1.43 | $1.02 | $1.04 | $1.24 | $1.34 | $1.45 | $1.00 |
| Avg Forecast | $3.20 | $2.82 | $2.65 | $2.47 | $2.85 | $2.54 | $2.37 | $2.28 | $2.62 | $2.32 | $2.12 | $1.98 | $2.35 | $2.17 | $2.00 | $1.86 | $2.15 | $2.19 | $1.98 | $1.92 | $2.02 | $1.96 | $1.82 | $1.49 | $1.77 | $1.52 | $1.27 | $0.98 | $1.57 | $1.42 |
| High Forecast | $3.24 | $2.87 | $2.69 | $2.51 | $2.90 | $2.58 | $2.41 | $2.31 | $2.63 | $2.36 | $2.13 | $1.98 | $2.39 | $2.19 | $2.06 | $1.89 | $2.18 | $2.22 | $1.98 | $1.92 | $2.02 | $2.00 | $1.82 | $1.49 | $1.77 | $1.52 | $1.27 | $0.98 | $1.57 | $1.42 |
| Low Forecast | $3.14 | $2.78 | $2.60 | $2.43 | $2.81 | $2.50 | $2.33 | $2.24 | $2.58 | $2.29 | $2.12 | $1.98 | $2.31 | $2.16 | $1.89 | $1.83 | $2.11 | $2.16 | $1.98 | $1.92 | $2.02 | $1.93 | $1.82 | $1.49 | $1.77 | $1.52 | $1.27 | $0.98 | $1.57 | $1.42 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.65% | 0.58% | 0.67% | 0.88% | 0.57% | -1.59% | 0.58% | 0.26% | -0.12% | 0.38% | 0.96% | 0.57% | 0.68% | 0.98% | 1.37% | 0.92% | 0.70% |
According to 1 Wall Street analysts, STERIS's projected average Quarter EPS for Mar 24 is $2.35, with a low estimate of $2.31 and a high estimate of $2.39. This represents a 65.49% increase compared to STE previous annual EPS of $1.42 (Dec 23).
STERIS Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BRKR | Bruker | $54.17 | $76.67 | 41.54% | Buy |
| CNMD | CONMED | $70.39 | $97.00 | 37.80% | Buy |
| LIVN | LivaNova | $50.73 | $67.00 | 32.07% | Buy |
| OFIX | Orthofix Medical | $18.71 | $24.00 | 28.27% | |
| STE | STERIS | $220.28 | $262.50 | 19.17% | Buy |
| ITGR | Integer | $143.22 | $153.50 | 7.18% | Buy |
| SNN | Smith & Nephew | $25.31 | $27.00 | 6.68% | Buy |
| SYK | Stryker | $391.07 | $413.17 | 5.65% | Buy |
| MASI | Masimo | $177.60 | $183.33 | 3.23% | Buy |
| ZIMV | ZimVie | $14.52 | $14.50 | -0.14% | Buy |
| IRTC | iRhythm | $110.34 | $107.29 | -2.76% | Buy |
| PODD | Insulet | $277.11 | $268.00 | -3.29% | Buy |
| GKOS | Glaukos | $159.01 | $152.00 | -4.41% | Buy |
| BSX | Boston Scientific | $102.71 | $97.44 | -5.13% | Buy |
| PEN | Penumbra | $269.73 | $232.09 | -13.95% | Buy |